MedTrace Logo

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

NCT07155252 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-03-06

No results posted yet for this study

Summary

This study aims at quantifying the accuracy of a self-administered fingerstick based glucose tolerance test (GTT@Home) respect to the gold-standard in-clinic venous plasma measures during the oral glucose tolerance test (OGTT) across a wide range of glycemic values in people at risk for clinical type 1 diabetes (T1D) (carriers of at least one islet autoantibody) or with new onset Stage 3 T1D within 100 days from the diagnosis.

Conditions

Interventions

DIAGNOSTIC_TEST

GTT@Home

self-administered fingerstick based glucose tolerance test

Sponsors & Collaborators

  • Breakthrough T1D

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Jennifer Sherr, MD · Yale University

Eligibility

Min Age
8 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-26
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07155252 on ClinicalTrials.gov